This study will be conducted in three cancer centres, namely the Tom Baker Cancer Centre, Calgary; the Cross Cancer Institute, Edmonton; and the Saskatoon Cancer Centre, Saskatoon. All patient related data will be collected in the individual institution and forwarded to the TBCC, the coordinating centre. Grade 3 or 4 toxicity and serious adverse events will be monitored and discussed among the co-investigators. Data entry and analysis will be performed at TBCC with statistical support from the Division of Population Health and Information at the centre.